Key result
Incretin therapies show emerging multi-system therapeutic potential beyond glucose and weight regulation.
Why the study?
Recent evidence suggests incretin therapies modulate pathways across multiple organ systems beyond glucose and weight regulation, prompting an evaluation of emerging indications.
This review highlights the emerging multi-system indications for incretin therapies beyond diabetes and obesity, emphasizing their pleiotropic anti-inflammatory and cardiorenal benefits.
Incretin therapies have revolutionized the management of type 2 diabetes and obesity. Recent evidence suggests that these agents modulate key pathways involved in cardiovascular, renal, hepatic, neuropsychiatric, and reproductive health. In this narrative review, we examine the role of incretin-based therapies in chronic kidney disease, heart failure with preserved ejection fraction, metabolic dysfunction-associated steatotic liver disease, neurodegenerative and cognitive disorders, substance use disorder, obstructive sleep apnea, knee osteoarthritis, and polycystic ovary syndrome. The mechanisms underlying these benefits appear to extend beyond glucose and weight regulation, including anti-inflammatory, neuroprotective, and cardiorenal effects. We summarize key clinical trial data, highlight knowledge gaps, and discuss future directions for integrating incretin-based therapies into broader clinical practice.
No takes yet. Share an insight, caveat, or question.
Alhomoud et al. (2025) conducted a review in Type 2 diabetes, obesity, and emerging indications (e.g., CKD, HFpEF, MASLD). Incretin therapies was evaluated. Incretin therapies demonstrate emerging therapeutic potential across cardiometabolic, renal, hepatic, and neuropsychiatric systems through mechanisms extending beyond glucose and weight regulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: